Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Fulcrum Pharma PLC (FUL)

  Print      Mail a friend

Thursday 07 February, 2002

Fulcrum Pharma PLC

Re Agreement

Fulcrum Pharma PLC
7 February 2002

For Immediate Release:                        07.00, Thursday, 7th February 2002

                         FULCRUM PHARMA DEVELOPMENTS LTD


Hemel Hempstead, UK - Fulcrum Pharma plc (LSE: FUL), the independent drug
development company, announced today that it has successfully completed the
first milestone of its multi-year agreement with Xenova Group plc (LSE: XEN;
Nasdaq: XNVA) thus enabling clinical trials of their next generation oncology
product to commence. The next milestone target is to take the product through to
proof of concept.

Dr Jon Court, Fulcrum's Chief Executive Officer, welcomed this extension of the
relationship, saying:

'This is a significant contract for Fulcrum and we are delighted to continue our
relationship with Xenova following the successful completion of the preclinical
evaluation and technical development of XR11576. Fulcrum has delivered
regulatory, Ethics and hospital board approval, to initiate the first clinical
trial of Xenova's next-generation oncology product, XR11576, thus enabling human
studies to begin. This was achieved on budget. Our next goal is to provide the
infrastructure and expertise necessary to move this new product rapidly through
to proof of concept in the clinic.'

                                    - ENDS -

For further information, please contact :

Fulcrum Pharma plc
Jon Court, Chief Executive                                       0700 392 1103
Neil Oughton, Director Business Development                      0700 392 1105

Buchanan Communications                                          0207 466 5000
Nicola How / Louise Bolton

Xenova Group plc                                                 01753 706600
Hilary Reid-Evans

Notes to Editors:

Fulcrum Pharma plc is an independent, drug development company that is the first
to offer global virtual drug development and strategic outsourcing services to
the pharmaceutical industry.

The Company has expertise in the design, execution and delivery of drug
development programmes and relies on state of the art information technology and
infrastructure in the supply of its services.

Through Fulcrum's services to its clients, the Directors believe that there is
the capacity to deliver products faster and more efficiently to the global
pharmaceutical market. Fulcrum does this by using its skills in the design of
drug programmes that deliver the necessary information for decision-making and
product registration. In so doing, Fulcrum works closely with its clients to
meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange.

                      This information is provided by RNS
            The company news service from the London Stock Exchange


a d v e r t i s e m e n t